Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Flaherty

Showing results (411-420 of 580) with videos related to

Pageof 58
Sort By:
Cancer Discovery|April 29, 2014
A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitorsDavid J Konieczkowski, Cory M Johannessen, Omar Abudayyeh, et al.
Science Translational Medicine|August 2, 2013
TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanomaRyan B Corcoran, Stephen Michael Rothenberg, Aaron N Hata, et al.
CA: a Cancer Journal for Clinicians|October 14, 2017
Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manualJeffrey E Gershenwald, Richard A Scolyer, Kenneth R Hess, et al.
European Journal of Cancer (Oxford, England : 1990)|August 23, 2019
Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and managementHelen J Gogas, Keith T Flaherty, Reinhard Dummer, et al.
Cell Reports|June 2, 2015
Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 DeregulationHyungsoo Kim, Dennie T Frederick, Mitchell P Levesque, et al.
Nature Metabolism|November 14, 2022
Myeloid-derived itaconate suppresses cytotoxic CD8<sup>+</sup> T cells and promotes tumour growthHongyun Zhao, Da Teng, Lifeng Yang, et al.
European Journal of Cancer (Oxford, England : 1990)|May 9, 2024
COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanomaDirk Schadendorf, Reinhard Dummer, Keith T Flaherty, et al.
Oncogene|June 16, 2015
Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cellsI V Fedorenko, E V Abel, J M Koomen, et al.
Plos One|July 2, 2014
Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimeticsDennie T Frederick, Roberto A Salas Fragomeni, Aislyn Schalck, et al.
Nature Medicine|October 6, 2020
Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-iReinhard Dummer, Celeste Lebbé, Victoria Atkinson, et al.
Pageof 58

Showing results (411-420 of 580) with videos related to

Sort By:
Pageof 58
Cancer Discovery|April 29, 2014
A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitorsDavid J Konieczkowski, Cory M Johannessen, Omar Abudayyeh, et al.
Science Translational Medicine|August 2, 2013
TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanomaRyan B Corcoran, Stephen Michael Rothenberg, Aaron N Hata, et al.
CA: a Cancer Journal for Clinicians|October 14, 2017
Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manualJeffrey E Gershenwald, Richard A Scolyer, Kenneth R Hess, et al.
European Journal of Cancer (Oxford, England : 1990)|August 23, 2019
Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and managementHelen J Gogas, Keith T Flaherty, Reinhard Dummer, et al.
Cell Reports|June 2, 2015
Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 DeregulationHyungsoo Kim, Dennie T Frederick, Mitchell P Levesque, et al.
Nature Metabolism|November 14, 2022
Myeloid-derived itaconate suppresses cytotoxic CD8<sup>+</sup> T cells and promotes tumour growthHongyun Zhao, Da Teng, Lifeng Yang, et al.
European Journal of Cancer (Oxford, England : 1990)|May 9, 2024
COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanomaDirk Schadendorf, Reinhard Dummer, Keith T Flaherty, et al.
Oncogene|June 16, 2015
Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cellsI V Fedorenko, E V Abel, J M Koomen, et al.
Plos One|July 2, 2014
Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimeticsDennie T Frederick, Roberto A Salas Fragomeni, Aislyn Schalck, et al.
Nature Medicine|October 6, 2020
Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-iReinhard Dummer, Celeste Lebbé, Victoria Atkinson, et al.
Pageof 58